Antibody-drug conjugates: recent advances in conjugation and linker chemistries
- Standort
-
Deutsche Nationalbibliothek Frankfurt am Main
- ISSN
-
1674-8018
- Umfang
-
Online-Ressource
- Sprache
-
Englisch
- Anmerkungen
-
online resource.
- Erschienen in
-
Antibody-drug conjugates: recent advances in conjugation and linker chemistries ; day:14 ; month:10 ; year:2016 ; pages:1-14
Protein & cell ; (14.10.2016), 1-14
- Urheber
-
Tsuchikama, Kyoji
- Beteiligte Personen und Organisationen
-
An, Zhiqiang
SpringerLink (Online service)
- DOI
-
10.1007/s13238-016-0323-0
- URN
-
urn:nbn:de:1111-2016111311082
- Rechteinformation
-
Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Letzte Aktualisierung
-
14.08.2025, 10:56 MESZ
Datenpartner
Dieses Objekt wird bereitgestellt von:
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Beteiligte
- Tsuchikama, Kyoji
- An, Zhiqiang
- SpringerLink (Online service)
Ähnliche Objekte (12)
Impact of Different Conjugation Approaches on Physicochemical Stability of Antibody-Drug Conjugates
Antibody–drug conjugates in ovarian cancer
Antibody–drug conjugates—the magic bullet?
Antibody-drug conjugates for the treatment of lymphoma: clinical advances and latest progress
Antibody–drug conjugates treatment of small cell lung cancer: advances in clinical research
Fate of Antibody-Drug Conjugates in Cancer Cells
Antibody–drug conjugates (ADCs) in lung cancer treatment
Ethynylphosphonamidates in the Synthesis of Antibody–Drug Conjugates
Safety and Tolerability of Antibody-Drug Conjugates in Cancer
Potential of antibody–drug conjugates (ADCs) for cancer therapy
Antibody–drug conjugates in the treatment of lymphoid neoplasms
Antibody–drug conjugates as an emerging therapy in oncodermatology
Impact of Different Conjugation Approaches on Physicochemical Stability of Antibody-Drug Conjugates
Antibody–drug conjugates in ovarian cancer
Antibody–drug conjugates—the magic bullet?
Antibody-drug conjugates for the treatment of lymphoma: clinical advances and latest progress
Antibody–drug conjugates treatment of small cell lung cancer: advances in clinical research
Fate of Antibody-Drug Conjugates in Cancer Cells
Antibody–drug conjugates (ADCs) in lung cancer treatment
Ethynylphosphonamidates in the Synthesis of Antibody–Drug Conjugates
Safety and Tolerability of Antibody-Drug Conjugates in Cancer
Potential of antibody–drug conjugates (ADCs) for cancer therapy
Antibody–drug conjugates in the treatment of lymphoid neoplasms
Antibody–drug conjugates as an emerging therapy in oncodermatology
Impact of Different Conjugation Approaches on Physicochemical Stability of Antibody-Drug Conjugates
Antibody–drug conjugates in ovarian cancer
Antibody–drug conjugates—the magic bullet?
Antibody-drug conjugates for the treatment of lymphoma: clinical advances and latest progress
Antibody–drug conjugates treatment of small cell lung cancer: advances in clinical research
Fate of Antibody-Drug Conjugates in Cancer Cells
Antibody–drug conjugates (ADCs) in lung cancer treatment
Ethynylphosphonamidates in the Synthesis of Antibody–Drug Conjugates
Safety and Tolerability of Antibody-Drug Conjugates in Cancer
Potential of antibody–drug conjugates (ADCs) for cancer therapy
Antibody–drug conjugates in the treatment of lymphoid neoplasms